AR032752A1 - Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa - Google Patents
Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasaInfo
- Publication number
- AR032752A1 AR032752A1 ARP000106608A ARP000106608A AR032752A1 AR 032752 A1 AR032752 A1 AR 032752A1 AR P000106608 A ARP000106608 A AR P000106608A AR P000106608 A ARP000106608 A AR P000106608A AR 032752 A1 AR032752 A1 AR 032752A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- substituted
- ring
- propionamids
- carbon atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
- C07C275/48—Y being a hydrogen or a carbon atom
- C07C275/50—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Detergent Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Ureido propionamidas o propionamidas heteroaromáticas trans olefínicas 2,3-di-sustituidas siendo dicha sustitucion en la posicion 2 un grupo fenilo sustituido y en la posicion 3 un anillo cicloalquílico, segun formula (1), en donde R1 y R2 son independientemente hidrogeno, halo, amino, nitro, perfluoro-alquilo inferior, alquilo inferior tio, alquilo inferior sulfonilo, alquilo inferior sulfonil metilo, perfluoro-alquilo inferior sulfonilo, o alquilo inferior sulfinilo; R es -(CH2)m-R3 o alquilo inferior C2-4; R3 es cicloalquilo C3-8, formula (2); R4 es o un anillo heteroaromático de 5 o 6 miembros no sustituido o mono-sustituido conectado a través de un átomo de carbono del anillo al grupo amino mostrado, conteniendo dicho anillo heteroaromático de 5 o 6 miembros de 1 a 2 heteroátomos seleccionados del grupo formado por azufre o nitrogeno, siendo uno de los heteroátomos un nitrogeno adyacente al átomo de carbono del anillo de conexion; es dicho anillo heteroaromático mono-sustituido está mono-sustituido en una posicion de un átomo de carbono del anillo diferente a la adyacente a dicho átomo de carbono de conexion, con un sustituyente seleccionado del grupo formado por halo o formula (3), donde m es 0 o 1; n es 0, 1, 2, 3 o 4; R7 es hidrogeno o alquilo inferior; y delta designa una configuracion trans respecto al doble enlace; o una sal farmacéuticamente aceptable del mismo. Siendo dichas propionamidas activadores de la glucoquinasa; un proceso para su preparacion, composicion farmacéutica que los comprenden y el uso de los mismos para la manufactura de un medicamento, que aumenta la secrecion de insulina en el tratamiento de la diabetes tipo H.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17078399P | 1999-12-15 | 1999-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032752A1 true AR032752A1 (es) | 2003-11-26 |
Family
ID=22621235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000106608A AR032752A1 (es) | 1999-12-15 | 2000-12-13 | Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US6353111B1 (es) |
| EP (1) | EP1242397B1 (es) |
| JP (1) | JP3824936B2 (es) |
| KR (1) | KR100502032B1 (es) |
| CN (1) | CN1185219C (es) |
| AR (1) | AR032752A1 (es) |
| AT (1) | ATE305461T1 (es) |
| AU (1) | AU781029B2 (es) |
| CA (1) | CA2392903C (es) |
| CO (1) | CO5050295A1 (es) |
| CZ (1) | CZ20022412A3 (es) |
| DE (1) | DE60022903T2 (es) |
| DK (1) | DK1242397T3 (es) |
| ES (1) | ES2249322T3 (es) |
| GC (1) | GC0000264A (es) |
| HK (1) | HK1054383B (es) |
| HR (1) | HRP20020514A2 (es) |
| HU (1) | HUP0203753A3 (es) |
| IL (2) | IL150083A0 (es) |
| JO (1) | JO2180B1 (es) |
| MA (1) | MA26855A1 (es) |
| MX (1) | MXPA02005874A (es) |
| MY (1) | MY125484A (es) |
| NO (1) | NO323142B1 (es) |
| NZ (1) | NZ518974A (es) |
| PE (1) | PE20011022A1 (es) |
| PL (1) | PL355815A1 (es) |
| RU (1) | RU2245332C2 (es) |
| TW (1) | TWI262916B (es) |
| UY (1) | UY26483A1 (es) |
| WO (1) | WO2001044216A1 (es) |
| YU (1) | YU41402A (es) |
| ZA (1) | ZA200203829B (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102300D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102299D0 (sv) * | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102764D0 (sv) * | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| JP2005518391A (ja) | 2001-12-21 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | Ｇｋ活性化剤としてのアミド誘導体 |
| WO2003068242A1 (en) | 2002-02-11 | 2003-08-21 | Vertex Pharmaceuticals Incorporated | Phospholipids as caspase inhibitor prodrugs |
| EP1496052B1 (en) | 2002-03-26 | 2009-08-05 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| CN1678311A (zh) | 2002-06-27 | 2005-10-05 | 诺沃挪第克公司 | 用作治疗剂的芳基羰基衍生物 |
| MXPA05000130A (es) | 2002-06-27 | 2005-02-17 | Novo Nordisk As | Derivados de aril-carbonilo como agentes terapeuticos. |
| EP1549626A1 (en) * | 2002-10-03 | 2005-07-06 | Novartis AG | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226930D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| US7132425B2 (en) | 2002-12-12 | 2006-11-07 | Hoffmann-La Roche Inc. | 5-substituted-six-membered heteroaromatic glucokinase activators |
| AU2003294376A1 (en) * | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heteroaryl compounds |
| PL378117A1 (pl) * | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| WO2004072066A1 (en) * | 2003-02-11 | 2004-08-26 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| WO2005066145A1 (en) | 2004-01-06 | 2005-07-21 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
| EP2048137A1 (en) | 2004-02-18 | 2009-04-15 | AstraZeneca AB | Benzamide derivatives and their use as glucokinase activating agents. |
| JP2007530631A (ja) * | 2004-04-02 | 2007-11-01 | ノバルティス アクチエンゲゼルシャフト | チアゾロピリジン誘導体、それを含む医薬組成物およびグルコキナーゼ介在性状態の処置法 |
| JP4700684B2 (ja) * | 2004-04-02 | 2011-06-15 | ノバルティス アーゲー | ２型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体 |
| US20080242869A1 (en) * | 2004-04-21 | 2008-10-02 | Matthew Fyfe | Tri(Cyclo) Substituted Amide Compounds |
| TW200600086A (en) | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| WO2005123132A2 (en) * | 2004-06-17 | 2005-12-29 | Novo Nordisk A/S | Use of liver-selective glucokinase activators |
| BRPI0514147A (pt) * | 2004-08-12 | 2008-05-27 | Prosidion Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratamento profilático ou terapêutico de uma condição onde a ativação de gk é desejável, de tratamento profilático ou terapêutico da hiperglicemia ou diabete e de prevenção da diabete em um ser humano que demosntra hiperglicemia pré-diabética ou toleráncia à glicose prejudicada, e, processo para a preparação do composto |
| MX2008000294A (es) | 2005-07-08 | 2008-04-04 | Novo Nordisk As | Activadores de dicicloalquil urea glucocinasa. |
| BRPI0622262A2 (pt) | 2005-07-09 | 2011-08-09 | Astrazeneca Ab | composto, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
| ES2426345T3 (es) | 2005-07-20 | 2013-10-22 | Eli Lilly And Company | Compuesto unidos en posición 1-amino |
| JP2007063225A (ja) * | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| WO2007039177A2 (en) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals |
| GT200600428A (es) * | 2005-09-30 | 2007-05-21 | Compuestos organicos | |
| GT200600429A (es) * | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| BRPI0618062A2 (pt) * | 2005-11-03 | 2011-08-16 | Prosidion Ltd | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para a preparação de um composto |
| CA2629223C (en) | 2005-11-17 | 2013-08-06 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
| EP1948614A2 (en) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
| EP2001875A2 (en) | 2006-03-08 | 2008-12-17 | Takeda San Diego, Inc. | Glucokinase activators |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| WO2007143434A2 (en) * | 2006-05-31 | 2007-12-13 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents |
| ES2581765T3 (es) | 2006-08-24 | 2016-09-07 | University Of Tennessee Research Foundation | Acilanilidas sustituidas y métodos de uso de las mismas |
| TW200825060A (en) | 2006-10-26 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| US7902248B2 (en) * | 2006-12-14 | 2011-03-08 | Hoffmann-La Roche Inc. | Oxime glucokinase activators |
| JP5419706B2 (ja) | 2006-12-20 | 2014-02-19 | タケダ カリフォルニア インコーポレイテッド | グルコキナーゼアクチベーター |
| TW200831081A (en) | 2006-12-25 | 2008-08-01 | Kyorin Seiyaku Kk | Glucokinase activator |
| CN101622231B (zh) | 2007-02-28 | 2013-12-04 | 艾德维纳斯医疗私人有限公司 | 作为葡糖激酶激活剂的2，2，2-三取代的乙酰胺衍生物、它们的制造方法和药学应用 |
| EP2116533B1 (en) * | 2007-03-07 | 2013-07-10 | Kyorin Pharmaceutical Co., Ltd. | Glucokinase activator |
| WO2008116107A2 (en) * | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| ATE513830T1 (de) * | 2007-09-21 | 2011-07-15 | Sanofi Aventis | Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| AR070107A1 (es) * | 2008-01-15 | 2010-03-17 | Lilly Co Eli | R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia |
| AU2009205070A1 (en) | 2008-01-18 | 2009-07-23 | Astellas Pharma Inc. | Phenyl acetamide derivative |
| SI2275414T1 (sl) | 2008-04-28 | 2015-10-30 | Kyorin Pharmaceutical Co., Ltd., | Ciklopentilakrilamidni derivat |
| BRPI0912802A2 (pt) | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
| WO2010150280A1 (en) | 2009-06-22 | 2010-12-29 | Cadila Healthcare Limited | Disubstituted benzamide derivatives as glucokinase (gk) activators |
| DK2459554T3 (da) | 2009-07-31 | 2014-01-06 | Cadila Healthcare Ltd | Substituerede benzamidderivater som glucokinase (GK)-aktivatorer |
| KR100970871B1 (ko) * | 2009-11-30 | 2010-07-20 | 케이제이알디 (주) | 바닥재 어셈블리 및 바닥재의 시공방법 |
| MY159151A (en) | 2009-12-04 | 2016-12-15 | Nissan Chemical Ind Ltd | 2-pyridone compounds |
| CN102959076B (zh) | 2010-03-31 | 2015-09-16 | 斯克里普斯研究所 | 重编程细胞 |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| LT2872482T (lt) | 2012-07-13 | 2020-12-28 | Oncternal Therapeutics, Inc. | Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| PT2921489T (pt) | 2012-11-13 | 2017-12-01 | Nissan Chemical Ind Ltd | Composto de 2-piridona |
| GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
| JP2021526130A (ja) | 2018-06-12 | 2021-09-30 | ブイティーブイ・セラピューティクス・エルエルシー | インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8909574D0 (en) | 1989-04-26 | 1989-06-14 | Ici Plc | Chemical process |
| US5169951A (en) | 1990-04-23 | 1992-12-08 | Ciba-Geigy Corporation | Process for preparing nematicidal compositions |
| PT1169312E (pt) * | 1999-03-29 | 2005-01-31 | Hoffmann La Roche | Activadores de glicocinase |
-
2000
- 2000-12-01 US US09/727,624 patent/US6353111B1/en not_active Expired - Fee Related
- 2000-12-11 JO JO2000197A patent/JO2180B1/en active
- 2000-12-12 IL IL15008300A patent/IL150083A0/xx unknown
- 2000-12-12 WO PCT/EP2000/012612 patent/WO2001044216A1/en active IP Right Grant
- 2000-12-12 KR KR10-2002-7007709A patent/KR100502032B1/ko not_active IP Right Cessation
- 2000-12-12 EP EP00987392A patent/EP1242397B1/en not_active Expired - Lifetime
- 2000-12-12 AU AU23652/01A patent/AU781029B2/en not_active Ceased
- 2000-12-12 CA CA002392903A patent/CA2392903C/en not_active Expired - Fee Related
- 2000-12-12 JP JP2001544706A patent/JP3824936B2/ja not_active Expired - Fee Related
- 2000-12-12 NZ NZ518974A patent/NZ518974A/en unknown
- 2000-12-12 DE DE60022903T patent/DE60022903T2/de not_active Expired - Lifetime
- 2000-12-12 HU HU0203753A patent/HUP0203753A3/hu unknown
- 2000-12-12 CZ CZ20022412A patent/CZ20022412A3/cs unknown
- 2000-12-12 CN CNB008172943A patent/CN1185219C/zh not_active Expired - Fee Related
- 2000-12-12 PL PL00355815A patent/PL355815A1/xx unknown
- 2000-12-12 PE PE2000001324A patent/PE20011022A1/es not_active Application Discontinuation
- 2000-12-12 DK DK00987392T patent/DK1242397T3/da active
- 2000-12-12 AT AT00987392T patent/ATE305461T1/de not_active IP Right Cessation
- 2000-12-12 ES ES00987392T patent/ES2249322T3/es not_active Expired - Lifetime
- 2000-12-12 RU RU2002118339/04A patent/RU2245332C2/ru not_active IP Right Cessation
- 2000-12-12 MX MXPA02005874A patent/MXPA02005874A/es active IP Right Grant
- 2000-12-12 YU YU41402A patent/YU41402A/sh unknown
- 2000-12-13 MY MYPI20005851A patent/MY125484A/en unknown
- 2000-12-13 GC GCP20001095 patent/GC0000264A/en active
- 2000-12-13 CO CO00094817A patent/CO5050295A1/es unknown
- 2000-12-13 AR ARP000106608A patent/AR032752A1/es active IP Right Grant
- 2000-12-14 TW TW089126672A patent/TWI262916B/zh active
- 2000-12-14 UY UY26483A patent/UY26483A1/es not_active Application Discontinuation
-
2002
- 2002-05-14 ZA ZA200203829A patent/ZA200203829B/en unknown
- 2002-06-06 IL IL150083A patent/IL150083A/en not_active IP Right Cessation
- 2002-06-12 HR HR20020514A patent/HRP20020514A2/hr not_active Application Discontinuation
- 2002-06-14 MA MA26690A patent/MA26855A1/fr unknown
- 2002-06-14 NO NO20022863A patent/NO323142B1/no not_active IP Right Cessation
-
2003
- 2003-09-16 HK HK03106627.5A patent/HK1054383B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032752A1 (es) | Ureido propionamidas o propionamidas heteroaromaticas trans olefinicas 2,3-di-sustituidas, un proceso para su preparacion, composiciones farmaceuticas que los comprenden y el uso de las mismas para la manufactura de un medicamento como activadores de glucoquinasa | |
| AR031066A1 (es) | Un compuesto que comprende una amida, un proceso para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
| AR031718A1 (es) | Tetrazolil-fenil acetamida activadores de glucoquinasa, un proceso para su preparacion, composicion farmaceutica, un proceso para su preparacion y el empleo de dichos compuestos para la preparacion de un medicamento | |
| PE20020056A1 (es) | Fenil amidas para-aril o heteroaril sustituidas como activadores de la glucoquinasa | |
| AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| AR032626A1 (es) | Amidas, composiciones farmaceuticas que las comprenden, proceso para preparar dichas composiciones, uso de dichas amidas en la preparacion de medicamentos, y proceso para la preparacion de dichas amidas | |
| YU84791A (sh) | Biciklicni 1-aza-cikloalkalni | |
| CO5580771A2 (es) | Antagonistas ccr5 como agentes terapeuticos | |
| AR030279A1 (es) | Derivados de fenilamida para-amino sustituida activadora de la glucoquinasa, un procedimiento para su preparacion, composiciones farmaceuticas y el empleo de dichos derivados para la preparacion de medicamentos. | |
| AR036672A1 (es) | Derivados de pirrolidinona | |
| HUP0302451A2 (hu) | (Tio)karbamoil-ciklohexán származékok, eljárás előállításukra és ezeket hatóanyagként tartalmazó gyógyszerkészítmények | |
| RU2008142834A (ru) | Модуляция церамидкиназы | |
| CO5590895A2 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos | |
| ECSP056016A (es) | Nuevos derivados de 2-piridinacarboxamida | |
| AR087046A2 (es) | Compuestos derivados de 4-oxoquinolina | |
| AR056321A1 (es) | COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS | |
| AR030053A1 (es) | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas | |
| TW200617001A (en) | Novel glucitol derivative, its prodrug, their salt and diabetic therapeutic agent containing the same | |
| UY28132A1 (es) | Derivados de pirrolopirimidina | |
| PE20050090A1 (es) | Indol-3-carboxamidas como activadores de glocoquinasa | |
| ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
| AR019789A2 (es) | Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento | |
| HUP0004436A2 (hu) | FP agonistákként alkalmazható aromás C16-C20-szubsztituált tetrahidroprosztaglandinok | |
| EA200600694A1 (ru) | Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |